# COLOPLAST B

Summary updated: 2026-03-20T02:10:12.496578Z
Canonical: https://finbar.com/research/companies/coloplast-b

## Overview

Coloplast A/S is a Danish medical device company focused on products for people with intimate healthcare needs. Its core business spans five areas: Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology, and Voice and Respiratory Care, with key products including ostomy bags and accessories, intermittent catheters and bowel-care devices, wound dressings and biologics, urology products, and technologies for people living with a neck stoma. The company states that its mission is to make life easier for people with intimate healthcare needs. [1](https://app.finbar.com/go?id=P-ff4e61a774954e0d9f6b78198a96f6a6)[2](https://app.finbar.com/go?id=P-4ede6a5370394ce6ae9e3db3ad2cbc4e)[3](https://app.finbar.com/go?id=P-aef10a78742d47fab785bf62eab0ec35)[4](https://app.finbar.com/go?id=P-4b9a12ba32e64e878ff6abec46ff8cbe)[5](https://app.finbar.com/go?id=P-d3e0dbad5aa948ccb70ae8e8080dc805)[6](https://app.finbar.com/go?id=P-825a875a02df4344adc518c161cbd2fb)

Coloplast operates globally, with activities across European markets, other developed markets such as the US, Canada, Japan, Australia and New Zealand, and emerging markets. The company employs more than 16,500 people and reports a presence in 41 countries. In fiscal 2023/24, revenue was DKK 27.0 billion, indicating a large international footprint within the medtech sector. [7](https://app.finbar.com/go?id=P-d2e32cf6db824209ae28566763d7204a)[8](https://app.finbar.com/go?id=P-b521b315a4bd41169726e6f6beb6d45a)[9](https://app.finbar.com/go?id=P-7aa96496e50543c9bb1b0ca0b3bd7fe6)[10](https://app.finbar.com/go?id=P-41991bb5fd4545b1b607dd105872037e)[11](https://app.finbar.com/go?id=P-17bc4c0b81f748aeaa7d92414a9c6ef7)[12](https://app.finbar.com/go?id=P-f7a1b8fb30b546c5aeb2f17f402f6ba7)[13](https://app.finbar.com/go?id=P-0a05ca6afa0640cab3c1fb2d44fbc194)
[1](https://app.finbar.com/go?id=P-ff4e61a774954e0d9f6b78198a96f6a6)[2](https://app.finbar.com/go?id=P-4ede6a5370394ce6ae9e3db3ad2cbc4e)[3](https://app.finbar.com/go?id=P-aef10a78742d47fab785bf62eab0ec35)[4](https://app.finbar.com/go?id=P-4b9a12ba32e64e878ff6abec46ff8cbe)[5](https://app.finbar.com/go?id=P-d3e0dbad5aa948ccb70ae8e8080dc805)[6](https://app.finbar.com/go?id=P-825a875a02df4344adc518c161cbd2fb)[7](https://app.finbar.com/go?id=P-d2e32cf6db824209ae28566763d7204a)[8](https://app.finbar.com/go?id=P-b521b315a4bd41169726e6f6beb6d45a)[9](https://app.finbar.com/go?id=P-7aa96496e50543c9bb1b0ca0b3bd7fe6)[10](https://app.finbar.com/go?id=P-41991bb5fd4545b1b607dd105872037e)[11](https://app.finbar.com/go?id=P-17bc4c0b81f748aeaa7d92414a9c6ef7)[12](https://app.finbar.com/go?id=P-f7a1b8fb30b546c5aeb2f17f402f6ba7)[13](https://app.finbar.com/go?id=P-0a05ca6afa0640cab3c1fb2d44fbc194)

## Products & services

Coloplast’s product portfolio is concentrated in chronic-care devices and consumables. In 2023/24, Ostomy Care generated DKK 9,545m of external revenue, Continence Care DKK 8,540m, Voice and Respiratory Care DKK 2,110m, Interventional Urology DKK 2,775m, and Advanced Wound Care DKK 4,060m out of a DKK 27,030m total, making ostomy and continence products the largest contributors to group revenue.[14](https://app.finbar.com/go?id=T-24f3c00918224b9392931fde202614b7) In ostomy care, Coloplast’s core brands are Alterna, Assura, SenSura, SenSura Mio and Brava, with Heylo added as a digital leakage notification system.[15](https://app.finbar.com/go?id=P-de634e2daf64414b8b735bcabfd9a448) Ostomy bags are sold as 1-piece or 2-piece systems built around an adhesive base plate and bag, and the adhesive is designed to provide a secure seal against leakage while being removable without causing skin damage or irritation.[16](https://app.finbar.com/go?id=P-4adb65621eea45129cd84536e58a3796) SenSura Mio is positioned as a full-shape ostomy line with flat, convex and concave options and uses BodyFit Technology.[17](https://app.finbar.com/go?id=P-cd8a61ed3afe4abaae3b2923e989764c) In continence care, the main brands are SelfCath, SpeediCath and Luja; the SpeediCath range covers male and female products in standard, compact and flexible formats as well as set solutions, and the portfolio also includes SpeediCath Navi for emerging and lower-priced markets.[18](https://app.finbar.com/go?id=P-0dcf168dbde546dcb8a63fe87a391d06)[19](https://app.finbar.com/go?id=P-a811cd5a57ea4ea1ace8d3a184892093) SpeediCath is described as an instantly ready-to-use hydrophilic catheter, while Luja is an intermittent catheter built around Micro-hole Zone Technology.[20](https://app.finbar.com/go?id=P-50b6442582b94ed7b50df3eb840f4ec7) In bowel care, Coloplast offers Peristeen Plus as a high-volume transanal irrigation system and Peristeen Light as a low-volume irrigation device.[21](https://app.finbar.com/go?id=P-d54207f943174c37a8003b17f79acfb1)

In Voice and Respiratory Care, key products include Provox Life Home HME, Provox Life Adhesive and the Provox Vega voice prosthesis.[22](https://app.finbar.com/go?id=P-c17b88676de149ab8e0aaf6fbb712b0f)[23](https://app.finbar.com/go?id=P-f19ea98fc6c34fc786aee8f13e530480)[24](https://app.finbar.com/go?id=P-c050ff29608b4c64861d8c1db15d5531) These products are used after laryngectomy, when patients breathe through a stoma and rely on heat-and-moisture exchangers for humidification and filtration of air; the recommended usage pattern is 3-4 voice prostheses per year, 2-3 HMEs per day and 1-2 adhesives per day.[25](https://app.finbar.com/go?id=P-bb4e8b84a13d4dde989e87a3abd84281)[26](https://app.finbar.com/go?id=P-c4215cf71d624dd2a3b9322fb539fc04) Coloplast has also introduced the Provox Life portfolio for situational use and uses a direct-to-consumer model for a substantial share of laryngectomy sales.[27](https://app.finbar.com/go?id=P-ffb2e55f9f634c48a9126127da9f7b21) In Interventional Urology, the company operates across Men’s Health, Women’s Health, Endourology and Bladder Health & Surgery.[28](https://app.finbar.com/go?id=P-c01ff2bb470345c48f64eba7ab59020e) Named products include the Titan Touch inflatable penile implant and the Altis and Restorelle brands for women’s health, which include vaginal slings for continence restoration and synthetic mesh products for pelvic-floor repair.[29](https://app.finbar.com/go?id=P-cc2a352735bc44d98330a6db5c270127)

Advanced Wound Care includes advanced dressings, skin care, Compeed contract manufacturing and biologics; advanced dressings account for around 50% of Advanced Wound Care sales, biologics around 25%, skin care around 15% and Compeed around 10%.[30](https://app.finbar.com/go?id=P-a926b70c4945407eb6692ca5c70ffa6a) The advanced dressings portfolio includes Biatain Silicone with 3DFit Technology and Biatain Fiber, reflecting a focus on silicone foams and gelling fibres.[31](https://app.finbar.com/go?id=P-e47c2d0ee5424a2baad4da180359280c) Skin care products include disinfectant liquids and creams for skin protection, wound cleansing and moisture-associated skin damage, and InterDry is marketed for prevention and treatment of skin-fold problems such as fungal infections, damaged skin and odour nuisance.[32](https://app.finbar.com/go?id=P-268a3a059a48453291b406686b18da9f)[33](https://app.finbar.com/go?id=P-a9b8de358fd649dfbb2d7de777ba3580) The biologics portfolio includes Kerecis fish-skin products, made from gently processed fish skin whose natural proteins, elastin, glycans and lipid structures remain intact, resulting in a product described as highly similar to human skin; these products can be stored at room temperature and have a three-year shelf life.[34](https://app.finbar.com/go?id=P-a96b4d12ff9b41c88aab23f708cec3d9)[35](https://app.finbar.com/go?id=P-786c9fc0e4d34257801dc5ae2a14d361) Coloplast also provides contract manufacturing of Compeed, a plaster product for blisters and cold sores.[36](https://app.finbar.com/go?id=P-75f981562c0d4743a75033ced685de2f)
[14](https://app.finbar.com/go?id=T-24f3c00918224b9392931fde202614b7)[15](https://app.finbar.com/go?id=P-de634e2daf64414b8b735bcabfd9a448)[16](https://app.finbar.com/go?id=P-4adb65621eea45129cd84536e58a3796)[17](https://app.finbar.com/go?id=P-cd8a61ed3afe4abaae3b2923e989764c)[18](https://app.finbar.com/go?id=P-0dcf168dbde546dcb8a63fe87a391d06)[19](https://app.finbar.com/go?id=P-a811cd5a57ea4ea1ace8d3a184892093)[20](https://app.finbar.com/go?id=P-50b6442582b94ed7b50df3eb840f4ec7)[21](https://app.finbar.com/go?id=P-d54207f943174c37a8003b17f79acfb1)[22](https://app.finbar.com/go?id=P-c17b88676de149ab8e0aaf6fbb712b0f)[23](https://app.finbar.com/go?id=P-f19ea98fc6c34fc786aee8f13e530480)[24](https://app.finbar.com/go?id=P-c050ff29608b4c64861d8c1db15d5531)[25](https://app.finbar.com/go?id=P-bb4e8b84a13d4dde989e87a3abd84281)[26](https://app.finbar.com/go?id=P-c4215cf71d624dd2a3b9322fb539fc04)[27](https://app.finbar.com/go?id=P-ffb2e55f9f634c48a9126127da9f7b21)[28](https://app.finbar.com/go?id=P-c01ff2bb470345c48f64eba7ab59020e)[29](https://app.finbar.com/go?id=P-cc2a352735bc44d98330a6db5c270127)[30](https://app.finbar.com/go?id=P-a926b70c4945407eb6692ca5c70ffa6a)[31](https://app.finbar.com/go?id=P-e47c2d0ee5424a2baad4da180359280c)[32](https://app.finbar.com/go?id=P-268a3a059a48453291b406686b18da9f)[33](https://app.finbar.com/go?id=P-a9b8de358fd649dfbb2d7de777ba3580)[34](https://app.finbar.com/go?id=P-a96b4d12ff9b41c88aab23f708cec3d9)[35](https://app.finbar.com/go?id=P-786c9fc0e4d34257801dc5ae2a14d361)[36](https://app.finbar.com/go?id=P-75f981562c0d4743a75033ced685de2f)

## Geographic presence

Coloplast’s commercial footprint is reported across three geographic clusters: European markets, other developed markets, and emerging markets. European markets comprise the UK, Germany, France, the Nordics, Benelux, Austria, Switzerland, Italy, Spain, Denmark and Hungary; other developed markets comprise the US, Canada, Japan and Australia; and emerging markets cover the remaining markets, with production in China included in that cluster definition [37](https://app.finbar.com/go?id=P-abbe2d47db7f4a4e996094780d91fb28). In 2023/24, revenue was DKK 14.8bn in European markets, DKK 7.7bn in other developed markets, and DKK 4.5bn in emerging markets, making Europe the company’s largest sales region [38](https://app.finbar.com/go?id=P-798c453bb9d74d408a2de34118993946)[39](https://app.finbar.com/go?id=P-0e1f2f126c764f58aeb706234f4533fb)[40](https://app.finbar.com/go?id=P-3ecfcd704cdc4180be570bc5b7d2f0ea).

The company is headquartered in Humlebaek, Denmark [41](https://app.finbar.com/go?id=P-2c022ea123b743bb86d2b115b61c149b). At the end of 2023/24, it had 16,247 employees operating in 41 countries and representing 102 nationalities [11](https://app.finbar.com/go?id=P-17bc4c0b81f748aeaa7d92414a9c6ef7). Employee distribution was 9,996 in European markets, 4,313 in other developed markets, and 1,938 in emerging markets [42](https://app.finbar.com/go?id=T-f7c727db126144da9a141938b204a219)[37](https://app.finbar.com/go?id=P-abbe2d47db7f4a4e996094780d91fb28). On the operations side, Hungary accounts for around 70% of production volumes, and Coloplast has been expanding its manufacturing footprint through Costa Rica and Portugal; the Portugal site is expected to be operational in 2026 [43](https://app.finbar.com/go?id=P-501a31577bd14f8e8d09ab258bef8300)[44](https://app.finbar.com/go?id=P-40bd10fd90c54efab8ca8f556f3520f8).
[37](https://app.finbar.com/go?id=P-abbe2d47db7f4a4e996094780d91fb28)[38](https://app.finbar.com/go?id=P-798c453bb9d74d408a2de34118993946)[39](https://app.finbar.com/go?id=P-0e1f2f126c764f58aeb706234f4533fb)[40](https://app.finbar.com/go?id=P-3ecfcd704cdc4180be570bc5b7d2f0ea)[41](https://app.finbar.com/go?id=P-2c022ea123b743bb86d2b115b61c149b)[11](https://app.finbar.com/go?id=P-17bc4c0b81f748aeaa7d92414a9c6ef7)[42](https://app.finbar.com/go?id=T-f7c727db126144da9a141938b204a219)[43](https://app.finbar.com/go?id=P-501a31577bd14f8e8d09ab258bef8300)[44](https://app.finbar.com/go?id=P-40bd10fd90c54efab8ca8f556f3520f8)

## Business segments

Coloplast’s official segment reporting uses five operating segments: Chronic Care, Voice and Respiratory Care, Interventional Urology, Advanced Wound Dressings, and Biologics. In that structure, Ostomy Care and Continence Care are not separate reportable segments; they are combined as Chronic Care, while Advanced Wound Dressings covers wound and skin care products and Biologics is a separate tissue-based segment. Based on 2023/24 external revenue, the reported segment mix was approximately Chronic Care 66.9%, Advanced Wound Dressings 11.2%, Interventional Urology 10.3%, Voice and Respiratory Care 7.8%, and Biologics 3.8%. [45](https://app.finbar.com/go?id=P-acb2e9f2815b465aae3ef18fa73aaddd)[46](https://app.finbar.com/go?id=P-2add3b22a9d7464084c1b4d3b060f6d3)[14](https://app.finbar.com/go?id=T-24f3c00918224b9392931fde202614b7)

In the business-area view, Chronic Care is split into Ostomy Care and Continence Care. Ostomy Care accounted for about 35.3% of group revenue in 2023/24 and focuses on products for people with a stoma, including ostomy bags, baseplates and supporting products. Continence Care accounted for about 31.6% and addresses urinary retention, urinary incontinence, and bowel dysfunction through intermittent catheters, collecting devices and bowel care systems. Voice and Respiratory Care accounted for about 7.8% of revenue and is itself split mainly between laryngectomy (around two-thirds of sales) and tracheostomy (around one-third). Interventional Urology accounted for about 10.3% and spans four subsegments: Men’s Health, Women’s Health, Endourology, and Bladder Health & Surgery. [14](https://app.finbar.com/go?id=T-24f3c00918224b9392931fde202614b7)[47](https://app.finbar.com/go?id=P-c103bb947e9a4702b0fdab179a6671d5)[15](https://app.finbar.com/go?id=P-de634e2daf64414b8b735bcabfd9a448)[48](https://app.finbar.com/go?id=P-3a8998200cde49da8a5b3c25a632da78)[49](https://app.finbar.com/go?id=P-6adbee40da004a25a40eb211d20c2e75)[50](https://app.finbar.com/go?id=P-9dc9152662ce4fda9c551e8f89536d8a)[51](https://app.finbar.com/go?id=P-870ebf9d85a147f29be1ed51ab4be157)[28](https://app.finbar.com/go?id=P-c01ff2bb470345c48f64eba7ab59020e)

Coloplast also discusses Advanced Wound Care as a broader business area. This business includes four internal components: advanced dressings, skin care, Compeed contract manufacturing, and biologics; management says these represent roughly 50%, 15%, 10%, and 25% of Advanced Wound Care sales, respectively. Functionally, advanced dressings are used for exudate management in chronic, surgical and burn wounds, skin care addresses moisture- and incontinence-related skin damage, and biologic dressings are used across chronic, acute and burn wounds. Using the 2023/24 revenue table, Advanced Wound Care as a whole was about 15.0% of group revenue, made up of Advanced Wound Dressings at about 11.2% and Biologics at about 3.8%; separate external revenue for skin care is not disclosed. [30](https://app.finbar.com/go?id=P-a926b70c4945407eb6692ca5c70ffa6a)[52](https://app.finbar.com/go?id=P-ae292620f2f14943a436a1e1fb1b247a)[33](https://app.finbar.com/go?id=P-a9b8de358fd649dfbb2d7de777ba3580)[53](https://app.finbar.com/go?id=P-ac3865a702264df7be8b6df7de45cdc0)[14](https://app.finbar.com/go?id=T-24f3c00918224b9392931fde202614b7)
[45](https://app.finbar.com/go?id=P-acb2e9f2815b465aae3ef18fa73aaddd)[46](https://app.finbar.com/go?id=P-2add3b22a9d7464084c1b4d3b060f6d3)[14](https://app.finbar.com/go?id=T-24f3c00918224b9392931fde202614b7)[47](https://app.finbar.com/go?id=P-c103bb947e9a4702b0fdab179a6671d5)[15](https://app.finbar.com/go?id=P-de634e2daf64414b8b735bcabfd9a448)[48](https://app.finbar.com/go?id=P-3a8998200cde49da8a5b3c25a632da78)[49](https://app.finbar.com/go?id=P-6adbee40da004a25a40eb211d20c2e75)[50](https://app.finbar.com/go?id=P-9dc9152662ce4fda9c551e8f89536d8a)[51](https://app.finbar.com/go?id=P-870ebf9d85a147f29be1ed51ab4be157)[28](https://app.finbar.com/go?id=P-c01ff2bb470345c48f64eba7ab59020e)[30](https://app.finbar.com/go?id=P-a926b70c4945407eb6692ca5c70ffa6a)[52](https://app.finbar.com/go?id=P-ae292620f2f14943a436a1e1fb1b247a)[33](https://app.finbar.com/go?id=P-a9b8de358fd649dfbb2d7de777ba3580)[53](https://app.finbar.com/go?id=P-ac3865a702264df7be8b6df7de45cdc0)

## Company history

Coloplast traces its origins to 1954, when nurse Elise Sørensen conceived the idea of an adhesive ostomy bag for her sister; Aage Louis-Hansen and Johanne Louis-Hansen developed the product, and the company was founded in Denmark in 1957.[54](https://app.finbar.com/go?id=P-dbbb848623fb4dbeaffffadf6149a6e3)[55](https://www.coloplast.com/about-coloplast/history/)

A major corporate milestone followed in 1983, when Coloplast’s B shares were listed on the Copenhagen Stock Exchange (now Nasdaq Copenhagen).[56](https://app.finbar.com/go?id=P-2a355ae8d38048d0876d37fd8e298efa) Another important step in its development came in 2006, when Coloplast completed the acquisition of Mentor Corporation’s urology business, significantly expanding its urology and continence offering.[57](https://www.coloplast.com/news-and-media/press-releases/archive/2006/coloplast-completes-acquisition-of-mentor-corporations-urology-business-significantly-expanding-coloplasts-urology-and-continence-global-product-offering-for-customers/) In the 2020s, Coloplast broadened further through the acquisition of Atos Medical in 2022 and Kerecis in 2023; it later described Atos Medical, Kerecis and Intibia as three strategic acquisitions completed during its Strive25 period.[58](https://view.news.eu.nasdaq.com/view?id=bf990ba83bb7aea8530ccbd71079902c1&lang=en)[59](https://www.globenewswire.com/news-release/2023/08/31/2734675/0/en/Coloplast-completes-the-acquisition-of-Kerecis.html)[60](https://app.finbar.com/go?id=P-15297fae95bd4f9fa08066e45679e05d)
[54](https://app.finbar.com/go?id=P-dbbb848623fb4dbeaffffadf6149a6e3)[56](https://app.finbar.com/go?id=P-2a355ae8d38048d0876d37fd8e298efa)[60](https://app.finbar.com/go?id=P-15297fae95bd4f9fa08066e45679e05d)[55](https://www.coloplast.com/about-coloplast/history/)[57](https://www.coloplast.com/news-and-media/press-releases/archive/2006/coloplast-completes-acquisition-of-mentor-corporations-urology-business-significantly-expanding-coloplasts-urology-and-continence-global-product-offering-for-customers/)[58](https://view.news.eu.nasdaq.com/view?id=bf990ba83bb7aea8530ccbd71079902c1&lang=en)[59](https://www.globenewswire.com/news-release/2023/08/31/2734675/0/en/Coloplast-completes-the-acquisition-of-Kerecis.html)

## Sources

1. [COLOPLAST B — Full financial report (2024 Y), p4](https://app.finbar.com/go?id=P-ff4e61a774954e0d9f6b78198a96f6a6)
2. [COLOPLAST B — Full financial report (2024 Y), p1](https://app.finbar.com/go?id=P-4ede6a5370394ce6ae9e3db3ad2cbc4e)
3. [COLOPLAST B — Full financial report (2024 Y), p3](https://app.finbar.com/go?id=P-aef10a78742d47fab785bf62eab0ec35)
4. [COLOPLAST B — Full financial report (2024 Y), p5](https://app.finbar.com/go?id=P-4b9a12ba32e64e878ff6abec46ff8cbe)
5. [COLOPLAST B — Full financial report (2024 Y), p32](https://app.finbar.com/go?id=P-d3e0dbad5aa948ccb70ae8e8080dc805)
6. [COLOPLAST B — Full financial report (2024 Y), p12](https://app.finbar.com/go?id=P-825a875a02df4344adc518c161cbd2fb)
7. [COLOPLAST B — Full financial report (2024 Y), p149](https://app.finbar.com/go?id=P-d2e32cf6db824209ae28566763d7204a)
8. [COLOPLAST B — Full financial report (2024 Y), p3](https://app.finbar.com/go?id=P-b521b315a4bd41169726e6f6beb6d45a)
9. [COLOPLAST B — Full financial report (2024 Y), p3](https://app.finbar.com/go?id=P-7aa96496e50543c9bb1b0ca0b3bd7fe6)
10. [COLOPLAST B — Full financial report (2024 Y), p3](https://app.finbar.com/go?id=P-41991bb5fd4545b1b607dd105872037e)
11. [COLOPLAST B — Full financial report (2024 Y), p54](https://app.finbar.com/go?id=P-17bc4c0b81f748aeaa7d92414a9c6ef7)
12. [COLOPLAST B — Full financial report (2024 Y), p16](https://app.finbar.com/go?id=P-f7a1b8fb30b546c5aeb2f17f402f6ba7)
13. [COLOPLAST B — Full financial report (2024 Y), p6](https://app.finbar.com/go?id=P-0a05ca6afa0640cab3c1fb2d44fbc194)
14. [COLOPLAST B — Full financial report (2024 Y), p83](https://app.finbar.com/go?id=T-24f3c00918224b9392931fde202614b7)
15. [COLOPLAST B — Full financial report (2024 Y), p19](https://app.finbar.com/go?id=P-de634e2daf64414b8b735bcabfd9a448)
16. [COLOPLAST B — Full financial report (2024 Y), p18](https://app.finbar.com/go?id=P-4adb65621eea45129cd84536e58a3796)
17. [COLOPLAST B — Full financial report (2024 Y), p19](https://app.finbar.com/go?id=P-cd8a61ed3afe4abaae3b2923e989764c)
18. [COLOPLAST B — Full financial report (2024 Y), p19](https://app.finbar.com/go?id=P-0dcf168dbde546dcb8a63fe87a391d06)
19. [COLOPLAST B — Full financial report (2024 Y), p24](https://app.finbar.com/go?id=P-a811cd5a57ea4ea1ace8d3a184892093)
20. [COLOPLAST B — Full financial report (2024 Y), p17](https://app.finbar.com/go?id=P-50b6442582b94ed7b50df3eb840f4ec7)
21. [COLOPLAST B — Full financial report (2024 Y), p19](https://app.finbar.com/go?id=P-d54207f943174c37a8003b17f79acfb1)
22. [COLOPLAST B — Full financial report (2024 Y), p25](https://app.finbar.com/go?id=P-c17b88676de149ab8e0aaf6fbb712b0f)
23. [COLOPLAST B — Full financial report (2024 Y), p25](https://app.finbar.com/go?id=P-f19ea98fc6c34fc786aee8f13e530480)
24. [COLOPLAST B — Full financial report (2024 Y), p25](https://app.finbar.com/go?id=P-c050ff29608b4c64861d8c1db15d5531)
25. [COLOPLAST B — Full financial report (2024 Y), p25](https://app.finbar.com/go?id=P-bb4e8b84a13d4dde989e87a3abd84281)
26. [COLOPLAST B — Full financial report (2024 Y), p25](https://app.finbar.com/go?id=P-c4215cf71d624dd2a3b9322fb539fc04)
27. [COLOPLAST B — Full financial report (2024 Y), p25](https://app.finbar.com/go?id=P-ffb2e55f9f634c48a9126127da9f7b21)
28. [COLOPLAST B — Full financial report (2024 Y), p32](https://app.finbar.com/go?id=P-c01ff2bb470345c48f64eba7ab59020e)
29. [COLOPLAST B — Full financial report (2024 Y), p32](https://app.finbar.com/go?id=P-cc2a352735bc44d98330a6db5c270127)
30. [COLOPLAST B — Full financial report (2024 Y), p28](https://app.finbar.com/go?id=P-a926b70c4945407eb6692ca5c70ffa6a)
31. [COLOPLAST B — Full financial report (2024 Y), p28](https://app.finbar.com/go?id=P-e47c2d0ee5424a2baad4da180359280c)
32. [COLOPLAST B — Full financial report (2024 Y), p28](https://app.finbar.com/go?id=P-268a3a059a48453291b406686b18da9f)
33. [COLOPLAST B — Full financial report (2024 Y), p28](https://app.finbar.com/go?id=P-a9b8de358fd649dfbb2d7de777ba3580)
34. [COLOPLAST B — Full financial report (2024 Y), p29](https://app.finbar.com/go?id=P-a96b4d12ff9b41c88aab23f708cec3d9)
35. [COLOPLAST B — Full financial report (2024 Y), p29](https://app.finbar.com/go?id=P-786c9fc0e4d34257801dc5ae2a14d361)
36. [COLOPLAST B — Full financial report (2024 Y), p28](https://app.finbar.com/go?id=P-75f981562c0d4743a75033ced685de2f)
37. [COLOPLAST B — Full financial report (2024 Y), p125](https://app.finbar.com/go?id=P-abbe2d47db7f4a4e996094780d91fb28)
38. [COLOPLAST B — Full financial report (2024 Y), p3](https://app.finbar.com/go?id=P-798c453bb9d74d408a2de34118993946)
39. [COLOPLAST B — Full financial report (2024 Y), p3](https://app.finbar.com/go?id=P-0e1f2f126c764f58aeb706234f4533fb)
40. [COLOPLAST B — Full financial report (2024 Y), p3](https://app.finbar.com/go?id=P-3ecfcd704cdc4180be570bc5b7d2f0ea)
41. [COLOPLAST B — Full financial report (2024 Y), p149](https://app.finbar.com/go?id=P-2c022ea123b743bb86d2b115b61c149b)
42. [COLOPLAST B — Full financial report (2024 Y), p125](https://app.finbar.com/go?id=T-f7c727db126144da9a141938b204a219)
43. [COLOPLAST B — Full financial report (2024 Y), p15](https://app.finbar.com/go?id=P-501a31577bd14f8e8d09ab258bef8300)
44. [COLOPLAST B — Full financial report (2024 Y), p15](https://app.finbar.com/go?id=P-40bd10fd90c54efab8ca8f556f3520f8)
45. [COLOPLAST B — Full financial report (2024 Y), p82](https://app.finbar.com/go?id=P-acb2e9f2815b465aae3ef18fa73aaddd)
46. [COLOPLAST B — Full financial report (2024 Y), p18](https://app.finbar.com/go?id=P-2add3b22a9d7464084c1b4d3b060f6d3)
47. [COLOPLAST B — Full financial report (2024 Y), p18](https://app.finbar.com/go?id=P-c103bb947e9a4702b0fdab179a6671d5)
48. [COLOPLAST B — Full financial report (2023 Y), p26](https://app.finbar.com/go?id=P-3a8998200cde49da8a5b3c25a632da78)
49. [COLOPLAST B — Full financial report (2023 Y), p26](https://app.finbar.com/go?id=P-6adbee40da004a25a40eb211d20c2e75)
50. [COLOPLAST B — Full financial report (2023 Y), p26](https://app.finbar.com/go?id=P-9dc9152662ce4fda9c551e8f89536d8a)
51. [COLOPLAST B — Full financial report (2024 Y), p25](https://app.finbar.com/go?id=P-870ebf9d85a147f29be1ed51ab4be157)
52. [COLOPLAST B — Full financial report (2024 Y), p28](https://app.finbar.com/go?id=P-ae292620f2f14943a436a1e1fb1b247a)
53. [COLOPLAST B — Full financial report (2024 Y), p28](https://app.finbar.com/go?id=P-ac3865a702264df7be8b6df7de45cdc0)
54. [COLOPLAST B — Full financial report (2025 Y), p178](https://app.finbar.com/go?id=P-dbbb848623fb4dbeaffffadf6149a6e3)
55. [www.coloplast.com](https://www.coloplast.com/about-coloplast/history/)
56. [COLOPLAST B — Full financial report (2024 Y), p70](https://app.finbar.com/go?id=P-2a355ae8d38048d0876d37fd8e298efa)
57. [www.coloplast.com](https://www.coloplast.com/news-and-media/press-releases/archive/2006/coloplast-completes-acquisition-of-mentor-corporations-urology-business-significantly-expanding-coloplasts-urology-and-continence-global-product-offering-for-customers/)
58. [view.news.eu.nasdaq.com](https://view.news.eu.nasdaq.com/view?id=bf990ba83bb7aea8530ccbd71079902c1&lang=en)
59. [www.globenewswire.com](https://www.globenewswire.com/news-release/2023/08/31/2734675/0/en/Coloplast-completes-the-acquisition-of-Kerecis.html)
60. [COLOPLAST B — Full financial report (2025 Y), p5](https://app.finbar.com/go?id=P-15297fae95bd4f9fa08066e45679e05d)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.